Scarica l'app Stockscreener
7.47
4.60%
-0.36
Dopo l'orario di chiusura:
7.46
-0.010
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.83
Aprire:
$7.79
Volume 24 ore:
1.46M
Relative Volume:
0.30
Capitalizzazione di mercato:
$434.30M
Reddito:
$11.13M
Utile/perdita netta:
$-114.59M
Rapporto P/E:
-3.2296
EPS:
-2.313
Flusso di cassa netto:
$-113.96M
1 W Prestazione:
-3.98%
1M Prestazione:
-10.75%
6M Prestazione:
-76.06%
1 anno Prestazione:
+5.36%
Intervallo 1D:
$7.445
$7.81
Intervallo di 1 settimana:
$7.445
$8.27
Portata 52W:
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.47 | 434.30M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-14 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2026-09-01 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-08-25 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-08-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2026-07-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-07-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-07-30 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2026-07-30 | Downgrade | Maxim Group | Buy → Hold |
| 2026-07-30 | Downgrade | Oppenheimer | Outperform → Perform |
| 2026-07-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2026-07-28 | Downgrade | Alliance Global Partners | Buy → Neutral |
| 2026-07-27 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2026-07-27 | Downgrade | Roth Capital | Buy → Neutral |
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor reports 24-month data for Duchenne therapy deramiocel By Investing.com - Investing.com South Africa
What's Going On With Capricor Therapeutics Stock Monday? - Benzinga
Capricor Therapeutics (CAPR) Shares Drop 10% Despite Positive Du - GuruFocus
H.C. Wainwright Sees Mixed Signals in Capricor Therapeutics (CAP - GuruFocus
Capricor drops as deramiocel OLE data fails to quell regulatory concerns - Seeking Alpha
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November - Yahoo Finance
Roth Capital Maintains Neutral on Capricor Therapeutics (CAPR) A - GuruFocus
Capricor Therapeutics (CAPR) Reports Positive HOPE-3 Study Data on Deramiocel for Duchenne Muscular Dystrophy - GuruFocus
Capricor reports 24-month data for Duchenne therapy deramiocel - Investing.com
Capricor Therapeutics Reports Positive 24-Month HOPE-3 Data for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress - Yahoo Finance
After a year on placebo, patients’ arm-function decline rate was 76% lower on treatment - Stock Titan
Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada
Small-Cap Biotech Capricor Therapeutics (CAPR) Sees Elevated Sho - gurufocus.com
Capricor Therapeutics Shares Jump as Two-Year Data Bolster Duchenne Drug Case - finance.biggo.com
CAPR Stock Jumps As Analysts Hike Price Targets Into FDA Date - StocksToTrade
Capricor Therapeutics Stock Surges: What's Going On? - Benzinga
CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call - timothysykes.com
CAPR Stock Jumps As Analysts Hike Price Targets Ahead FDA Call - StocksToTrade
CAPR Stock Jumps As Analysts Hike Targets Ahead Of FDA Date - timothysykes.com
CAPR Stock Jumps As Street Hikes Price Targets Into FDA Catalyst - StocksToTrade
Capricor Therapeutics, Inc. stock Analysis: Bearish Trend and Intraday Pause - The Cryptonomist
Capricor Therapeutics (CAPR) Shares Surge on Positive Phase 3 Da - gurufocus.com
Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ) - Seeking Alpha
Total equity of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView
Return on equity % of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView
Recover Investment Losses: Class Action Initiated Against Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - 巴士的報
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - globenewswire.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline - PR Newswire
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action - TMX Newsfile
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - GlobeNewswire Inc.
CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - GlobeNewswire Inc.
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 28, 2026Contact Levi & Korsinsky - ACCESS Newswire
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 | FinancialContent - FinancialContent
CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, - globenewswire.com
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - Eastern Progress
CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy - stocktwits.com
Capricor Therapeutics Shareholder Alert: ClaimsFiler - globenewswire.com
SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026CAPR - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities LawsuitContact Levi & Korsinsky - Morningstar
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions - Yahoo Finance
Capricor Therapeutics, Inc. Notice of September 28, 2026 - globenewswire.com
Portnoy Law Firm Announces Class Action on Behalf of Capricor Therapeutics, Inc. Investors - GlobeNewswire Inc.
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT - globenewswire.com
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capricor Therapeutics Inc Azioni (CAPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
11,223 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
1.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):